MST Access Diagnostics Forum notice

Melbourne, Australia, 5 December 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that CEO Dr Leearne Hinch will deliver the attached presentation to investors and shareholders at the **MST Access Diagnostics Forum** on 6 December 2022.

The Diagnostics Forum details and link to register for the webinar are provided below:

Date:	Tuesday, 6 December 2022
Time:	10:40 AM AEDT
Registration:	MST Access Diagnostics Forum

Authorised for release by Company Secretary, Mark Edwards.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARDING LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

Investor Presentation

6 December 2022

MST Access Diagnostics Forum

ASX: IIQ

Disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

INOVIQ highlights

- Next-generation exosome capture tools and precision diagnostics
- Patented technology platforms for biomarker isolation and detection
- Products in-market for exosome research & bladder cancer
- Multi-product cancer diagnostics pipeline targeting large global markets
- Compelling early data in breast and ovarian cancers
- Multiple key inflection points over next 12 months

INOVIQ snapshot

Financial information (ASX:IIQ)	
Ordinary shares[2]	92,018,702
Listed options[2]	5,909,965
Share price[2]	A$0.630
Market capitalisation[2]	A$58.0m
Cash at bank[1]	A$13.5m
Ave monthly cash burn[3]	A$607k

Share price performance



Major shareholders (as at 2 December 2022)	
Merchant Funds Mgt Pty Ltd	14.2%
Moggs Creek Pty Ltd	5.3%
Dr Irmgard Irminger-Finger	3.8%
Peter Gunzburg	2.0%
TOP 20	**35.6%**

Board and Management	
Dr Geoff Cumming	Non-Executive Chairman
Mr Robert (Max) Johnston	Non-Executive Director
Mr Philip Powell	Non-Executive Director
Professor Allan Cripps AO	Non-Executive Director
Dr Leearne Hinch	Chief Executive Officer
Dr Greg Rice	Chief Scientific Officer
Mr Mark Edwards	Chief Financial Officer & Company Secretary

1. Cash at 30 Sep 2022 | 2. As at 2 Dec 2022.; 3. 3-months to 30 Sep 2022

INOVIQ

Pipeline | Multiple shots on goal

PRODUCT	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL DEVELOPMENT	REGISTRATION
hTERT[1]	Bladder Cancer	ICC	Adjunct to cytology				★ In-market
EXO-NET-RUO	Exosome Capture	Device	Research tool				★ In-market
Exosome-OC[2] **(OCRF-7)**	Ovarian Cancer	Multiomic	Screening				
SubB2M-BCM	Breast Cancer	Immunoassay	Monitoring				2023
SubB2M-OCM	Ovarian Cancer	Immunoassay	Monitoring				2023
SubB2M-SPR	Multi-cancer	SPR	Risk assessment				
SubB2M-PCS	Prostate Cancer	Immunoassay	Detection				
SubB2M-PaC	Pancreatic Cancer	Immunoassay	Detection				
BARD1-Ovarian[3]	Ovarian Cancer	Immunoassay	Detection				
BARD1-Breast[3]	Breast Cancer	Immunoassay	Detection				

**RUO = Research Use Only; ICC = Immunocytochemistry;*
1. Adjunct to urine cytology to assist the detection of bladder cancer; 2 Umbrella Research & Option Agreement with UQ, 3. Progression subject to completion of review (ASX: 28/3/22)

Indications for Use | Tests for different cancers and uses in the diagnostic pathway



Test use	Earlier detection in asymptomatic people	Aiding and confirming diagnosis	Staging and triage-to-treatment	Monitoring treatment response & disease recurrence
Existing tests	Screening mammography; PSA test	CT scan, MRI, PET, TVUS, ROCA, OVA1	BRACAnalysis CDx®	CA125 test, CA15.3 test
IIQ pipeline[1]	**Exosome OC test**	*future focus*	*future focus*	**SubB2M OC test** **SubB2M BC test**

1. Different products, with different uses and performance requirements.

Ovarian Cancer | Overview

- **#8** most common cancer & **#1** gynaecological cancer deaths in women worldwide
- UNMET NEED for earlier and more accurate tests for OC detection and monitoring



$1.9b[1]
OVARIAN CANCER

prevalence **823k**
Incidence **314k**
deaths **207k**

45%
Overall 5-year survival rate



5-year Survival by Stage at Diagnosis[2]

Normal	Stage 1	Stage 2	Stage 3	Stage 4
Healthy ovaries	Confined to ovaries	Spread within pelvis	Spread within abdomen	Spread to other organs
100%	95%	70%	25%	15%

Current Standard of Care[3]

Screening	No tests recommended to SCREEN average-risk, asymptomatic women for ovarian cancer
Monitoring	CA125 blood test approved to MONITOR treatment response and recurrence in women with ovarian cancer

1.: GLOBOCAN (IARC) 2020; & https://www.globenewswire.com/news-release/2019/08/07/1898453/0/en/Ovarian-Cancer-Diagnostics-Market-Size-Worth-US-1-8-Bn-by-2026.html
2. www.cancer.org; www.cancer.net; www.cancerresearchuk.org;3. USPSTF, ACS, ACOG, AGDH

INOVIQ

OC Screening | Exosomal ovarian cancer screening test

Collaboration with UQ to develop blood-based exosomal screening test for ovarian cancer[1]

- UQ's OCRF-7 validated in a retrospective case-control study achieving over **90% accuracy** for detection of stage I / II ovarian cancer[3]
- UQ project funded via a **$2.7m MRFF[2] grant**
- INOVIQ has the **exclusive option to license** the development and commercialisation rights
- Meets **critical need** for early detection of ovarian cancer to improve treatment options, women's health outcomes and help save lives



FIGURE: Retrospective case (n = 153) : control (n= 312) study comparing accuracy of OCRF-7 algorithm to CA-125 assay

1. The University of Queensland (UQ) (ASX: 1/4/22); 2. Medical Research Future Fund (MRFF); 3. Research supported by a grant from the Ovarian Cancer Research Foundation (OCRF)

INOVIQ

OC Screening | Exosomal OC test planned studies

Next-steps

1. **Ovarian Cancer 97 Study:** To establish that EXO-NET is fit-for-purpose for the downstream analysis of plasma extracellular vesicle associated microRNA and protein and for use in MRFF Ovarian Cancer Screening Study (UQ)
2. **OC 250 Study:** Analytical Validation study including plasma and serum comparison
3. **OC 3000 Study**: Clinical Validation study using 3000 samples obtained from the UKCTOCS study (Case : control ratio = 1:2)



1. The University of Queensland (UQ) (ASX: 1/4/22); 2. Medical Research Future Fund (MRFF);
3. Research supported by a grant from the Ovarian Cancer Research Foundation (OCRF)

INOVIQ

Breast Cancer | Overview

- **#1** most common cancer & **#1** cancer deaths in women worldwide
- UNMET NEED for earlier and more accurate tests for BC detection and monitoring



$4.2b[1]
BREAST CANCER

prevalence **7.8m**
incidence **2.3m**
deaths **685k**

85%
Overall 5-year survival rate



5-year Survival by Stage at Diagnosis[2]



Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Non-invasive <2cm	Invasive tumour <2.5cm	Tumour <5cm +/- axillary LN	Tumour >5cm & spread ax LN	Spread to other organs
100%	98%	90%	70%	25%

Current Standard of Care[3]

Screening	Annual or biennial screening with Mammogram for average-risk, asymptomatic women ages 45 - 74+ years
Monitoring	CA15.3 blood test approved to MONITOR treatment response and recurrence in women with breast cancer

1. https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market & GLOBOCAN (IARC) 2020; 2. www.cancer.org; www.cancer.net; www.cancerresearchuk.org. 3. USPSTF, ACS, ACOG, AGDH

INOVIQ

BC Monitoring | SubB2M-based Breast Cancer monitoring test

- SubB2M-based immunoassay development, optimisation and validation underway at ResearchDx[1,2]
- Commenced breast cancer clinical study (BC95) to evaluated performance of SubB2M-CA15.3 by cancer stage
- Interim data are encouraging and indicate that both early- and late-stage breast cancer samples can be discriminated from cancer-free (controls) samples.
- Next step is to establish reproducibility of the assay

BC 95 Study: Breast Cancer Clinical Study



Kruskal-Wallis Test chi^2 = 13.7, p = 0.001, Pair-wise comparisons – Dunn's Test (Bonferroni) .The median value and interquartile ranges are presented.

1. ResearchDx engaged under Master Services Agreement (ASX: 5/4/22); 2. SubB2M US patent grant and program update (ASX: 1/7/22);

BC Monitoring | SubB2M Breast Cancer monitoring study

Intended use: A blood test to aid in monitoring breast cancer recurrence

Prospectively Collected Retrospectively Analysed Longitudinal Breast Cancer Study	
Study Design	Prospective Longitudinal Clinical Cohort Study
Objective	CA15.3 is still a widely used test for monitoring breast cancer, although recent reports discourage its routine use because of low sensitivity. This is a prospective study to evaluate the efficacy of Neu5Gc-CA15.3 (a cancer-specific glycovariant) in monitoring breast cancer recurrence.
Description	200 patients with a histologically/pathologically confirmed diagnosis of breast cancer and recurrence or metastasis after surgery. Peripheral venous blood collected every 3 to 6 months. Serum concentrations of Neu5Gc-CA15.3 (INOVIQ) and CA15.3 (Elecsys® CA 125 II (Roche)) will be measured at different follow-up time points.
Clinical Samples	Previously bio-banked samples
Primary Outcome Measure	Neu5G-CA15.3 not inferior to CA15.3 (as assessed by Cox proportional hazards models with a time-varying indicator)
Secondary Outcome Measure	Sensitivity of Neu5Gc-CA15.3 > CA15.3

INOVIQ

BC Monitoring | SubB2M Breast Cancer monitoring study (cont.)

Intended use: A blood test to aid in monitoring breast cancer recurrence

Post-treatment histologically/ pathologically confirmed diagnosis of breast cancer (n=200)

↓

Serum samples collected at 3,6,12,24,48 months

↓

Neu5Gc-CA15.3 & CA15.3 concentrations measured

↓

Data Analysis – Hazard Ratio



INOVIQ

Cancer Risk Assessment | SubB2M-based SPR test

- POC data in case-control studies showed the SubB2M-based SPR test detected:
  - Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) [1,2]
  - Breast Cancer at 95% sensitivity and 100% specificity across all stages (n = 118) [1,2,3]
- Commenced transfer, development and evaluation of SubB2M-based SPR test on Nicoya's next-gen Alto digital SPR instrument[4]
- In development for **cancer risk assessment** in conjunction with approved screening tests
- Potential for further development as a **multi-cancer detection test**

Breast Cancer data

SENSITIVITY BY STAGE[1]

n=118 (96 cancers : 22 controls)



Ovarian Cancer data

SENSITIVITY BY STAGE

n=69 (47 cancers : 22 controls)



POC = Proof of Concept; SPR = Surface Plasmon Resonance; OC = Ovarian Cancer; CRO = Contract Research Organisation

1. Shewell et al. N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. BMC Cancer (2022) 22:334: https://rdcu.be/cJ21m; ;
2. Samples provided by Victorian Cancer Biobank;
3. Collaborative Research Agreement with the Institute for Glycomics at Griffith University; 4. ResearchDx engaged under Master Services Agreement (ASX: 5/4/22)
4. Contract Research Agreement with Nicoya Lifesciences Inc (ASX: 13/10/22

INOVIQ

Diagnostics | Commercialisation strategy

Stepped approach to commercialisation:

- Market entry: Initially US, then expand to EU, AU and others
- Regulatory: Initially LDT, then IVD route
- Indication for use: Initially monitoring (SubB2M), or triage / high-risk screening (Exosomal OC), before general screening
- Clinical: Evidence of clinical performance in intended use population
- Partnering: CLIA-accredited high complexity Lab for commercialization of tests as LDTs

Laboratory Developed Test (LDT)	In Vitro Diagnostic (IVD)
CLIA	FDA 510k clearance / PMA approval
Development & validation in a single laboratory	Larger-scale clinical studies required
Laboratory partner	Distribution partner
Diagnostic service provided to laboratories and clinicians	Kits for sale to hospitals, clinical laboratories and doctors' offices
Faster and lower cost, delivers early revenue & establishes market acceptance	Slower and higher cost, delivers wider clinical adoption & revenue growth

FDA = US Food & Drug Administration

Market potential | Screening and monitoring

Statistics[1]	Eligible screening population[2]	Screening market size[3]	Eligible monitoring population[4]	Monitoring market size[5]
Ovarian cancer incidence **52,638**	4.0 / 54.7 / 119m / 60.4	0.6 / 8.2 / USD $18b / 9.1	11.5 / 167.3 / 367k / 188.3	1.7 / 25.1 / USD $55m / 28.0
Ovarian cancer prevalence **154,831**	(Millions of people)	(US$ billions)	(Thousands of people)	(US $millions)



Breast cancer incidence **543,972**	4.0 / 54.7 / 119m / 60.4	0.6 / 8.2 / USD $18b / 9.1	0.2 / 2.1 / 4.46m / 2.2	24.9 / 312.7 / USD $668m / 331.2
Breast cancer prevalence **2,279,467**	(Millions of people)	(US$ billions)	(Millions of people)	(US $millions)

1 Source: https://gco.iarc.fr/today/home covering US, EU5 and AU . 2. Females 50-79yrs covering US, EU5 and AU (Source: https://www.populationpyramid.net). 3. Assumed cancer screening test price US$150 per test 4 Monitoring population based on 4x prevalence plus 1x incidence 5. Assumed cancer monitoring test price at US$150 per test (Source: MST Access: INOVIQ Limited Research Report 25 August 2022); 4 https://www.globenewswire.com/news-release/2019/08/07/1898453/0/en/Ovarian-Cancer-Diagnostics-Market-Size-Worth-US-1-8-Bn-by-2026.html ; 5 https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market

INOVIQ

Exosomes | Diagnostic and therapeutic potential



Exosomes are small extracellular vesicles (sEVs; 30-150nm) released from most cells, including cancer cells, into body fluids (plasma, saliva, urine, CSF)

EXOSOMES contain biomolecules (DNA, RNAs, proteins) and deliver these "messages" between cells



Exosomes can be captured and their messages "read" to determine the disease or health status of a cell

Potential diagnostic and therapeutic applications for cancer, metabolic, inflammatory, neurodegenerative and other diseases

INOVIQ

EXO-NET I Exosome isolation tools

- **EXO-NET pan-exosome capture** is a 'research use only' (RUO) product for isolation of exosomes from body fluids
- Meets and unmet need for **rapid, efficient and scalable isolation** of exosomes
- **Suitable** for biomarker discovery, research & development phases of future exosome-based diagnostics & therapeutics
- Expanding **EXO-NET pipeline** including TEXO-NET for cancer EVs, NEURO-NET for bdEVs[1], automated and HTP EXO-NET solutions compatible with routine pathology workflows
- **Collaborating** with KOLs to validate EXO-NET for cancer, inflammatory, metabolic and neurodegenerative diseases
- **Direct sales** of EXO-NET products to Universities & Research Institutes
- Partnered with Percorso Life Sciences for contract sales team & logistics services in the US to **accelerate commercial roll-out**[4]
- Initial **sales campaign to >1000 researchers** is expected to deliver results in 1H CY2023

GLOBAL MARKET OPPORTUNITY FOR EXOSOME RESEARCH MARKET

US$661 million

1. brain-derived Extracellular Vesicles; I3. NOVIQ engages US-based contract sales team to accelerate EXO-NET roll out (ASX: 21/7/22)

EXO-NET | Speed, purity and yield advantages

FAST	Easy and convenient workflow with EV capture in 15 minutes
SAMPLE VERSATILITY	Optimal solution for very low volume and rare samples from plasma, urine, saliva
HIGH YIELD	High yield and capture of EVs from various biofluids
PURITY	Reduced co-isolation of contaminants and high enrichment of EV RNA and protein markers
DOWNSTREAM COMPATIBILITY	Compatible for use with most downstream applications (qPCR, Mass Spec, ELISA)
CUTOMIZABLE	Customizable to isolate specific EV subpopulations for use in target disease indications
SCALABLE	Suitable for automation and high-throughput screening

INOVIQ

EXO-NET I Efficient Isolation of plasma EV derived RNAs

EXONET outperforms or is equivalent to 4 commercial EV isolation kits for recovery of EV micro RNA (miRNA) and messenger (mRNA) as indicated by lower CT values.[1,2]

"The use of a scalable exosome isolation tool such as INOVIQ's EXO-NET product is critical to enable the commercialisation of routine exosome-based tests that can be used in pathology laboratories worldwide."

Associate Professor Carlos Salomon Gallo
Head of Exosome Biology Laboratory, University of Queensland



1. INOVIQ data 2 Evaluation by leading Australian Research Institute

Key achievements of 2022 and catalysts for 2023



INOVIQ

Contacts



INOVIQ Ltd

23 Normanby Road
Notting Hill VIC 3168
Australia

p. +61 3 9548 7586

e. info@inoviq.com

w. www.inoviq.com

Dr Leearne Hinch
Chief Executive Officer

e. lhinch@inoviq.com

m. +61 400 414 416

Board and Management

DR GEOFF CUMMING PhD
Non-Executive Chairman

Healthcare and biotechnology director with extensive diagnostics industry experience.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre International Ltd and MD/CEO of Anteo Diagnostics Ltd.

Currently NED AnteoTech Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Previously President and CEO of Johnson & Johnson Pacific, NED of PolyNovo Ltd and CannPal Animal Therapeutics Ltd, and Chairman of AusCann Ltd.

Currently NED of Medical Developments International Ltd & Tissue Repair Ltd, and interim CEO of PolyNovo Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at Polynovo Ltd and Medical Developments International Ltd.

Currently NED RMA Global Ltd.

Prof ALLAN CRIPPS AO PhD
Non-Executive Director

Distinguished academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services.

Previously Pro Vice Chancellor (Health) at Griffith University where he was responsible for the establishment of the Health Faculty including the School of Medicine.

Currently Professor Emeritus at Griffith University and NED of Neurotech International Ltd.

DR LEEARNE HINCH
Chief Executive Officer

Experienced biotechnology CEO with expertise in corporate development, capital raising, product development, commercialisation and licensing.

Past leadership and consulting roles in ASX-listed biotechnology, multinational and private companies across diagnostics, devices, therapeutics and animal health including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Virbac & Mars.

DR GREG RICE PhD
Chief Scientific Officer

Internationally recognised scientist with over 30 years' experience and a successful track record in oncology research, biomarker trials and diagnostics commercialisation.

Previous leadership roles in academia and industry including UQ, Baker Heart Institute, UoM, Monash & HealthLinx.

MARK EDWARDS
CFO & Company Secretary

Highly experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies including Medical Developments International and Cogstate.

Dr ROCCO IANNELLO
Business Development and Licensing Director

Senior business development professional and research scientist with experience in IP commercialisation, business development and licensing across medical devices & pharmaceuticals.

Strong Australian and international networks across government, academia, industry and venture capital. Previous senior roles at Monash, Ward Medication Management & Gordagen Pharmaceuticals.